Health · Medical Research · 8 hrs ago
Iptacopan blocked pancreatic cancer growth in a preclinical study
Researchers at Chiba University in Japan studied blocking complement factor B to slow pancreatic cancer.
They found that high levels of this enzyme around human pancreatic tumors were linked to poorer survival and more frequent cancer recurrence through the bloodstream.
In cancer cells and a mouse model, the approved drug iptacopan reduced cancer cell growth and tumor size.
Blocking the enzyme also changed the tumor environment, with fewer regulatory T cells and more cancer-fighting CD8+ T cells.
The strongest tumor suppression came from combining the blocker with chemotherapy and immunotherapy, suggesting it may help treatments work better together.
Pancreatic cancer is difficult to treat, and the five-year survival rate is below 15%.
Further preclinical and clinical studies are needed before researchers can establish whether this approach is safe and effective for people with pancreatic cancer.
A preclinical study found that iptacopan, which blocks complement factor B, suppressed pancreatic cancer growth.
The strongest tumor suppression was observed when the drug was combined with chemotherapy and immunotherapy.
In a mouse model, blocking complement factor B also changed the tumor immune environment, with fewer regulatory T cells and more CD8+ T-cell infiltration.
The researchers found that high complement factor B levels in tissue surrounding human pancreatic tumors were associated with poorer survival and more frequent recurrence through the bloodstream.
The researchers said further preclinical and clinical studies are needed before iptacopan’s potential as a combination treatment can be assessed.
- Who
- Researchers at Chiba University, including lead investigator Shigetsugu Takano and lead author Daren Zhou.
- What
- A preclinical study found that iptacopan suppressed pancreatic cancer growth and altered the tumor immune environment.
- When
- The study was published in 2026. The article was published on November 10, 2026.
- Where
- The research included human pancreatic ductal adenocarcinoma tissue and a mouse model. The researchers were at Chiba University in Japan.
- Why
- Researchers investigated complement factor B as a potential treatment target because it is associated with pancreatic cancer development and an immunosuppressive tumor environment.
This story does not have two clearly opposing sides.
Researchers found that high complement factor B levels in tissue surrounding human pancreatic tumors were associated with poorer survival and more frequent recurrence through the bloodstream.
Researchers tested iptacopan in pancreatic cancer cells and a mouse model, then explored combination treatment with immune checkpoint blockades.
The study was published in The American Journal of Pathology.
- Drug
- Iptacopan, a selective complement factor B inhibitor
- Cancer type
- Pancreatic ductal adenocarcinoma
- Study journal
- The American Journal of Pathology
- Publication year
- 2026
- Five-year survival rate
- Below 15% for pancreatic ductal adenocarcinoma
What people are saying
We demonstrated that iptacopan significantly suppressed tumor growth.
Our findings support iptacopan's potential as a combination therapy with chemotherapy and immunotherapy, although further preclinical and clinical studies are needed.